Joslin Diabetes Center's President and CEO Will Step Down at Year's End

Today, Peter S. Amenta, MD, PhD, announced that he will step down as President and CEO of Joslin Diabetes Center at the end of 2019. After that, he will remain an advisor to Joslin. The Board of Trustees has formed a Search Committee and has commenced a formal search for a new President and CEO.

"I have spent approximately 10 years here at Joslin, as a Trustee, consultant and finally President and CEO," said Dr. Amenta. "I can honestly say it has been a remarkable experience and one of the most enjoyable periods of my professional career. It has been my honor to lead this storied institution and contribute to its success. I will greatly miss the amazingly dedicated clinicians, researchers, educators, and staff at the heart of Joslin, whose commitment to those living with diabetes is unmatched. I am firmly convinced Joslin will lead the way into this most exciting decade of discovery and treatment of people with diabetes."

"Dr. Amenta oversaw the rejuvenation of Joslin and helped us continue to expand our national and international global outreach as we work to improve the lives of people with diabetes," said Joslin Board of Trustees Chair Ann Lagasse. "We are tremendously grateful for his service over the past decade."

Under Dr. Amenta's leadership, the Joslin Clinic has grown to treat more than 23,000 outpatients and inpatients each year. The Young Adult Program, to transition people with diabetes from pediatric services to adult services, was established on his watch and Joslin's IT infrastructure was transformed, in part, to develop programs to deliver novel care and education around the world.

The Research Division at Joslin has continued its success with his support, including receiving federal funding from the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), as one of only 16 designated Diabetes Research Centers. He has worked to assist in creating the Center for Cell-Based Therapy for Diabetes (CCTD) at Joslin and establish Joslin as a founding member of the Harvard-based Boston Autologous Islet Replacement Therapy Program (BAIRT), dedicated to developing novel cellular approaches to treat diabetes. The relationships Dr. Amenta has forged within the academic, clinical and philanthropic communities will benefit Joslin for years to come.

Dr. Amenta's relationship with Joslin began before his appointment as President and CEO, when he served on the Board of Trustees for approximately five years. Prior to accepting the President and CEO position at Joslin, Dr. Amenta served as a faculty member and staff physician respectively of Rutgers Robert Wood Johnson Medical School (RWJMS) and Robert Wood Johnson University Hospital in New Jersey, from 1989 ? 2015. He was Senior Vice President of Medical Affairs and Chief Medical Officer at the Hospital for four of those years. In 2006 he was named the interim dean of the medical school and then was appointed dean in 2008; he stepped down as dean in 2014, but remained on the faculty until leaving to lead Joslin. He was also CEO of the Robert Wood Johnson Medical Group, the school's faculty medical practice, from 2006-2014.

Joslin sincerely thanks Dr. Amenta for his comprehensive efforts and focus on advancing initiatives that are helping individuals, both locally and globally, to benefit from the world's best diabetes care, research and education.

About Joslin
Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 16 NIH-funded Diabetes Research Centers in the U.S.